9+ hour, 48+ min ago   (540+ words) Computed tomography has long been one of medicine’s most powerful windows into the human body, but a fundamental limitation has always lurked beneath its grayscale images. Conventional CT measures how much X-rays are attenuated as they pass through tissue, a…...

3+ day, 8+ hour ago   (161+ words) Investment will support Ride's Molecular Logistics™ platform with the goal of delivering genetic medicines to the lung for all people living with cystic fibrosis Ride's platform is designed to learn the rules of delivery by tracking the destinations of millions…...

3+ day, 21+ hour ago   (90+ words) TradingView Upcoming phase II data and regulatory updates for the OTC deficiency program will clarify the path forward for both pediatric and adult populations. The CF program is advancing with a 12-week open-label study, with a phase III decision and…...

1+ week, 1+ day ago   (161+ words) This role will be based in our New York City office (in the Financial District). You must be willing to work in the office 3 days per week on Tuesday, Wednesday and Thursday. You’ll work on problems that matter, at a…...

4+ day, 11+ hour ago   (322+ words) Updated · Sep 8, 2026 New York, NY – Sep 08, 2026 – Global Transport Protein Assays Kits Market size is expected to be worth around US$ 12.4 Billion by 2034 from US$ 3.8 Billion in 2024, growing at a CAGR of 12.6% during the forecast period 2025 to 2034. In 2024, North America led…...

4+ day, 22+ hour ago   (868+ words) //s27.q4cdn.com/906368049/files/pictures/2026/09082026_LEXX_1.png LEXX: Introducing DehydraTECH 3.0 Lexaria Bioscience Corp. (NASDAQ: LEXX) announced absorption data from its 2026 Animal Study #2 (GLP-1-A26-2). The canine study examined amycretin and retatrutide bioavailability using oral delivery compared to reference formats. 18 different study arms were evaluated,…...

5+ day, 18+ hour ago   (569+ words) BioSpace Aptar and Aceso Therapeutics Announce Collaboration to Advance Inhaled Antisense Oligonucleotide Therapy for Cystic Fibrosis Development program will support inhaled formulation development and device assessment for Aceso's ACT-101 candidate, reinforcing Aptar Pharma's upstream services capabilities in inhaled biologic development…...

5+ day, 21+ hour ago   (221+ words) Aptar's ACT-101 is designed to intervene a step earlier than current CF modulators. Drug delivery specialist Aptar Pharma is collaborating with Aceso Therapeutics to advance development for the latter’s ACT-101 – an inhalable antisense oligonucleotide (ASO) designed to treat the underlying…...

6+ day, 18+ hour ago   (214+ words) The province of Saskatchewan has announced that it is expanding the eligibility of those living with cystic fibrosis to a medication which improves lung function. People in Saskatchewan will now be able to take Alyftrek, a medication available for those…...